U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H26N2O2.BrH
Molecular Weight 407.345
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROQUININE HYDROBROMIDE

SMILES

Br.[H][C@]1(C[C@@H]2CCN1C[C@@H]2CC)[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3

InChI

InChIKey=BKKQYYLUFOIOJF-DSXUQNDKSA-N
InChI=1S/C20H26N2O2.BrH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3;1H/t13-,14-,19-,20+;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/international/hydroquinine.html http://www.genome.jp/dbget-bin/www_bget?dr:D08265

Hydroquinine (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. Hydroquinine also has antimalarial and demelanizing activity. It might be used to lightens light brown color patches on skin, age spots, skin discolorations associated with pregnancy, skin trauma or taking birth control pills. Hydroquinine is used in skin lightening creams and lotions because it is an effective bleaching agent, slowing the production of the tyrosinase enzyme and reducing the amount of melanin formed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
129.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Inhibin

Approved Use

Hydroquinine hydrobromide (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary.

Launch Date

1990
Curative
Unknown

Approved Use

Unknown
Primary
Hydroquinine

Approved Use

Hydroquinine is used for the treatment, control, prevention, and improvement of the following diseases, conditions and symptoms: Lightens light brown color patches on skin Age spots Skin discolorations associated with pregnancy Skin trauma Birth control pills Hormone replacement therapy during menopause
PubMed

PubMed

TitleDatePubMed
Antimalarial activity and interactions between quinine, dihydroquinine and 3-hydroxyquinine against Plasmodium falciparum in vitro.
1996 Sep-Oct
Patents

Patents

Sample Use Guides

200 mg with the evening meal and a further 100 mg at bedtime for 14 days
Route of Administration: Oral
In Vitro Use Guide
The median inhibitory concentration (IC50) for hydroquinine against Plasmodium falciparum in vitro was 129 nmol/L (range 54-324)
Name Type Language
HYDROQUININE HYDROBROMIDE
MART.   WHO-DD  
Common Name English
HYDROQUININE HBR
Common Name English
DIHYDROQUININE HYDROBROMIDE
Common Name English
HYDROQUININE HYDROBROMIDE [MART.]
Common Name English
CINCHONAN-9-OL, 10,11-DIHYDRO-6'-METHOXY-, MONOHBR, (8.ALPHA.,9R)-
Common Name English
CINCHONAN-9-OL, 10,11-DIHYDRO-6'-METHOXY-, MONOHYDROBROMIDE, (8.ALPHA.,9R)-
Common Name English
DIHYDROQUININE HBR
Common Name English
Hydroquinine hydrobromide [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
21125220
Created by admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
PRIMARY
SMS_ID
100000077620
Created by admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
PRIMARY
FDA UNII
Q26K81T6MC
Created by admin on Fri Dec 15 15:24:11 GMT 2023 , Edited by admin on Fri Dec 15 15:24:11 GMT 2023
PRIMARY
CAS
85153-19-1
Created by admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
PRIMARY
EVMPD
SUB14139MIG
Created by admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
PRIMARY
EVMPD
SUB36265
Created by admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
ALTERNATIVE
EPA CompTox
DTXSID901005573
Created by admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
PRIMARY
ECHA (EC/EINECS)
285-797-5
Created by admin on Fri Dec 15 15:24:10 GMT 2023 , Edited by admin on Fri Dec 15 15:24:10 GMT 2023
PRIMARY